Turn pilot data into the economic case a US payer can approve.
You have pilot data that proves your product works. Your payer conversations keep stalling on ROI. This bridge rebuilds your payer pitch in cost-avoidance, PMPM, and finance-team language.
US payers do not buy clinical outcomes. They buy cost avoidance.
Most HealthTech founders walk into payer meetings with clinical evidence and leave confused when the conversation stalls. The missing artifact is usually the economic case: what this costs versus saves over 18 months across high-utilisation members.
A medical director may agree your product works, but finance still needs a defensible PMPM and utilisation-reduction argument.
If the buyer cannot model cost avoidance per member per year, the payer conversation remains interesting but non-committal.
You need a dry, finance-ready 1-page summary a medical director can send internally without rewriting your pitch.
See why $797 is a low-friction decision.
Adjust the assumptions. Even a small lift in close probability can create a large expected-value upside when the payer contract is worth six or seven figures.
What the buyer receives.
Converts clinical outcome data into cost-per-member-per-year, utilisation reduction, and cost-avoidance language payer finance teams can model.
Maps how United, Aetna, BCBS, Cigna, and regional Blue plans may prioritise ROI, utilisation, member risk, and network economics differently.
Shows the three-stage path: pilot → value-based contract → broader coverage, including what typically triggers each next stage.
A dry, forwardable payer-style summary built from the founder’s pilot data and current pitch, designed for internal finance review.
Roleplay payer CFO and medical director objections so the founder has clear answers before cost, risk, and utilisation questions appear.
The pitch is rebuilt around the company’s actual pilot data, not generic market-size claims or vague clinical benefits.
From stalled payer pitch to finance-ready case.
Buyer shares pilot data, outcomes, utilisation metrics, and current payer pitch.
Clinical results are converted into cost avoidance, PMPM, and payer finance logic.
A 1-page payer economic summary is created in a dry, forwardable format.
60-minute roleplay covers CFO objections, medical director concerns, and next-step triggers.
Built for founders with warm US payer momentum.
Good fit
- You have pilot data or early clinical outcomes
- You already have a payer conversation, intro, or meeting scheduled
- Your pitch keeps stalling around ROI, cost, or adoption economics
- You sell to US payers, employers, risk-bearing providers, or health plans
- You need a stronger economic case before the next meeting
Not the right fit
- You do not have pilot data yet
- You need FDA/regulatory filing advice
- You are only doing brand awareness or generic marketing
- You need a full actuarial report or legal contracting review
- You do not have a payer-facing product or use case
Put the number in the room before the payer asks for it.
One US payer contract can be worth $500k–$5M. If better ROI framing improves your odds by even a small amount, the $797 fee becomes an obvious decision.